Virometix Announces Successful Closing of Series B Investment Round raising CHF 7.5 million
Jul 16, 2020•almost 5 years ago
Amount Raised
$5 Million
Round Type
series b
Description
Virometix, a privately held Swiss biotechnology company developing a new generation of vaccines and immunotherapeutic drugs for the prevention and treatment of infectious and oncology diseases, announced today that it has successfully completed a CHF 7.5 million Series B equity financing round.
FundzWatch™ Score
71
Medium Activity
Buyer Intent Analysis
Get personalized insights on buying likelihood